In summary, this study on primary biopsies demonstrates for the first time that BRAF/RAS mutation status alone is not generally associated with MEK/ERK pathway activation, and may therefore not predict for therapeutic response to MEK inhibition in MM. The gene discussed is MAP2K7; the disease is Miyoshi myopathy.